Zuri A. Murrell, MD, on Rising Colorectal Cancer Rates in Younger People

Video

The cancer specialist from Cedars-Sinai spoke about the observed increase of colorectal cancer in younger individuals, as well as the significantly higher incidence and death rates in black people.

According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer deaths in the US in men and women combined.

Further, while this disease typically affects older individuals, colorectal cancer is increasingly affecting people under the age of 50, who are now anticipated to account for 12% of all US cases in 2020. According to Zuri A. Murrell, MD, a colorectal surgeon and cancer specialist at Cedars-Sinai, obesity, diabetes, smoking, and a family history of colorectal cancer may all play a role in this observed increase

In an interview with CancerNetwork®, Murrell discussed this observed increase in younger individuals, as well as the significantly higher incidence and death rates in black people.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

American Cancer Society. Key Statistics for Colorectal Cancer. American Cancer Society website. Last revised August 31, 2020. Accessed September 14, 2020. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content